EUVIMEDEUVIMED entdecken
Open Access

Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke

Alec Stepanian iD, Richard J Travers iD, Angelina Tesfu, Nicole L Wolter iD, Joshua J Man, Qing Lu, Sohel Shamsuzzaman iD, Rebecca A Deaton iD, Gary K Owens iD, Christopher S Chen iD, Iris Z Jaffe iD

Circulation · 16.09.2025 · 152 (11) · 765-783

DOI: 10.1161/circulationaha.125.073610 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation, erschienen am 16.09.2025. Verfasst von Alec Stepanian und 10 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Cardiology Research Institute (A.S., R.J.T., A.T., N.L.W., J.J.M., Q.L., I.Z.J.), Tufts Medical Center, Boston, MA. Hauptthemen laut MEDLINE: Imidazoles, Pyridazines, Myocardial Infarction, Stroke. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: American Heart Association-American Stroke Association, NHLBI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Imatinib, the first Abl-tyrosine kinase inhibitor (TKI), improved leukemia outcomes without cardiovascular side effects. Newer agents, including ponatinib, addressed imatinib resistance, improving cancer remission, but substantially increased arterial thrombotic events, including myocardial infarction (MI) and stroke. The mechanism behind ponatinib-induced thrombosis and the cardiovascular effect of asciminib, a newly approved Abl-TKI, remain unknown. METHODS: The effect of clinically relevant plasma concentrations of imatinib, ponatinib, and asciminib were compared with vehicle in vivo using SR-BI-mut/LDLR–knockout (KO) mice to assess spontaneous MI and stroke risk. The mechanism was interrogated in C57BL/6J mice, assessing leukocyte trafficking and thromboinflammation by intravital microscopy and flow cytometry, respectively, and in ApoE-KO mice, assessing plaque phenotype by flow cytometry and histology. In vitro effects on human umbilical vein endothelial cells (ECs) and human coronary artery ECs were determined by flow cytometry, PCR, and immunoblotting. The role of TNF (tumor necrosis factor) signaling was evaluated by pharmacological inhibition and small interfering RNA knockdown. RESULTS: In SR-BI-mut/LDLR-KO mice, ponatinib significantly accelerated death from MI and stroke compared with vehicle, imatinib, and asciminib. In human ECs, only ponatinib increased expression of TNF receptors (TNFRs) and adhesion molecules (P-selectin, ICAM1 [intercellular adhesion molecule 1], and VCAM1 [vascular cell adhesion molecule 1]). Ponatinib rapidly induced TNFR2 membrane trafficking and TNF signaling in human umbilical vein ECs. TNFR inhibition or TNFR2 knockdown prevented ponatinib induction of EC adhesion molecules. In vivo, ponatinib increased mesenteric vessel adhesion molecules, leukocyte rolling and adhesion to vessels, leukocyte and platelet activation, and platelet–leukocyte aggregates. In ApoE-KO mice, ponatinib increased plaque necrotic core and inflammation, consistent with a rupture-prone phenotype. Asciminib-treated mice developed none of these in vitro or in vivo toxicities. In C57BL/6J mice, TNFR inhibition blocked ponatinib-induced mesenteric adhesion molecule expression and leukocyte trafficking, but not platelet–leukocyte aggregation. TNFR blockade prevented ponatinib-induced plaque inflammation in ApoE-KO mice and MI and stroke in SR-BI-mut/LDLR-KO mice. CONCLUSIONS: Ponatinib, a potent anticancer therapy, activates ECs, platelets, and leukocytes, driving plaque inflammation and death from MI and stroke in mice, mirroring clinical cardiotoxicities in patients with cancer. Asciminib did not induce these effects, suggesting it might be a safer option for imatinib-resistant patients with cancer. Inhibition of TNFR-mediated endothelial activation is sufficient to prevent ponatinib-induced major adverse cardiovascular events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImidazolesPyridazinesMyocardial InfarctionStrokePlaque, AtheroscleroticLeukocytesProtein Kinase InhibitorsBlood PlateletsTumor Necrosis Factor-alphaEndothelial CellsAnimalsHumansSignal TransductionMice, Inbred C57BLMiceInflammationHuman Umbilical Vein Endothelial CellsMice, KnockoutMaleMice, Knockout, ApoEPlatelet Activation

Stichwörter der Autor:innen

asciminib hydrochlorideatherosclerosiscardio-oncologyendothelial cellsimatinib mesylateinflammationponatinib hydrochloride

Substanzen

ponatinibImidazolesPyridazinesProtein Kinase InhibitorsTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Molecular Cardiology Research Institute (A.S., R.J.T., A.T., N.L.W., J.J.M., Q.L., I.Z.J.), Tufts Medical Center, Boston, MA.
  • Graduate School of Biomedical Sciences, Tufts University School of Medicine, Boston, MA (A.S., N.L.W., J.J.M., I.Z.J.).
  • Department of Medicine, Division of Hematology Oncology (R.J.T.), Tufts Medical Center, Boston, MA.
  • Robert M. Berne Cardiovascular Research Center, University of Virginia School of Medicine, Charlottesville (S.S., R.A.D., G.K.O.).
  • Department of Molecular Physiology and Biophysics, University of Virginia, Charlottesville (S.S., R.A.D., G.K.O.).
  • Department of Biomedical Engineering and the Biological Design Center, Boston University, MA (C.S.C.).

ORCID-Profile: Alec Stepanian, Richard J Travers, Nicole L Wolter, Sohel Shamsuzzaman, Rebecca A Deaton, Gary K Owens, Christopher S Chen, Iris Z Jaffe

Förderung

  • American Heart Association-American Stroke Association
  • NHLBI NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Stepanian, A., Travers, R. J., Tesfu, A., Wolter, N. L., Man, J. J., Lu, Q., Shamsuzzaman, S., Deaton, R. A., Owens, G. K., Chen, C. S., & Jaffe, I. Z. (2025). Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke. Circulation, 152(11), 765-783. https://doi.org/10.1161/circulationaha.125.073610

Vancouver

Stepanian A, Travers RJ, Tesfu A, Wolter NL, Man JJ, Lu Q, et al. Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke. Circulation. 2025;152(11):765-783. doi:10.1161/circulationaha.125.073610

BibTeX
@article{Stepanian2025,
  author = {Stepanian, Alec and Travers, Richard J and Tesfu, Angelina and Wolter, Nicole L and Man, Joshua J and Lu, Qing and Shamsuzzaman, Sohel and Deaton, Rebecca A and Owens, Gary K and Chen, Christopher S and Jaffe, Iris Z},
  title = {Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke},
  journal = {Circulation},
  year = {2025},
  volume = {152},
  number = {11},
  pages = {765--783},
  doi = {10.1161/circulationaha.125.073610}
}
Kostenlos starten →